BACKGROUND: Tumor mesothelin overexpression is present in different malignancies, including the majority of patients with pancreatic or biliary cancers. The objective of this study was to evaluate the use of shed serum mesothelin and megakaryocyte potentiating factor (MPF) concentrations as biomarkers for these cancers. METHODS: A total of 151 individuals, divided into five groups, were retrospectively analyzed: healthy donors (n=15), patients with benign non-pancreatic conditions (n=52), benign pancreatic conditions (n=33), biliary carcinoma (n=9), and pancreatic ductal adenocarcinoma (n=42). Mesothelin and MPF concentrations were measured in serum with the Mesomark™ and Human MPF ELISA, respectively. RESULTS: Mesothelin and MPF concentrations did not significantly differ among the five individual participant groups (p=0.34, p=0.33, respectively), nor did any other combination and pair-wise comparison of the participant groups demonstrated a significant difference in biomarker concentrations. In patients with pancreatic cancer, mesothelin or MPF concentrations were not associated with tumor stage (p=0.87, p=0.48, respectively) or differentiation grade (p=0.73, p=0.52, respectively). CONCLUSIONS: Serum mesothelin and MPF concentrations, measured with standard available ELISAs, were not specific for benign or pancreatic disease. Both biomarkers were not elevated in patients with pancreatic or biliary cancers, and consequently do not appear to be useful biomarkers for these malignancies.
BACKGROUND:Tumormesothelin overexpression is present in different malignancies, including the majority of patients with pancreatic or biliary cancers. The objective of this study was to evaluate the use of shed serum mesothelin and megakaryocyte potentiating factor (MPF) concentrations as biomarkers for these cancers. METHODS: A total of 151 individuals, divided into five groups, were retrospectively analyzed: healthy donors (n=15), patients with benign non-pancreatic conditions (n=52), benign pancreatic conditions (n=33), biliary carcinoma (n=9), and pancreatic ductal adenocarcinoma (n=42). Mesothelin and MPF concentrations were measured in serum with the Mesomark™ and HumanMPF ELISA, respectively. RESULTS:Mesothelin and MPF concentrations did not significantly differ among the five individual participant groups (p=0.34, p=0.33, respectively), nor did any other combination and pair-wise comparison of the participant groups demonstrated a significant difference in biomarker concentrations. In patients with pancreatic cancer, mesothelin or MPF concentrations were not associated with tumor stage (p=0.87, p=0.48, respectively) or differentiation grade (p=0.73, p=0.52, respectively). CONCLUSIONS: Serum mesothelin and MPF concentrations, measured with standard available ELISAs, were not specific for benign or pancreatic disease. Both biomarkers were not elevated in patients with pancreatic or biliary cancers, and consequently do not appear to be useful biomarkers for these malignancies.
Authors: Heather L Beyer; Ryan D Geschwindt; Curtis L Glover; Ly Tran; Ingegerd Hellstrom; Karl-Erik Hellstrom; M Craig Miller; Thorsten Verch; W Jeffrey Allard; Harvey I Pass; Niranjan Y Sardesai Journal: Clin Chem Date: 2007-02-08 Impact factor: 8.327
Authors: Raffit Hassan; Zoltan G Laszik; Megan Lerner; Mark Raffeld; Russell Postier; Daniel Brackett Journal: Am J Clin Pathol Date: 2005-12 Impact factor: 2.493
Authors: P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: Masanori Onda; Satoshi Nagata; Mitchell Ho; Tapan K Bera; Raffit Hassan; Richard H Alexander; Ira Pastan Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Raffit Hassan; Alan T Remaley; Maureen L Sampson; Jingli Zhang; Derrick D Cox; James Pingpank; Richard Alexander; Mark Willingham; Ira Pastan; Masanori Onda Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Ingegerd Hellstrom; John Raycraft; Sandra Kanan; Niranjan Y Sardesai; Thorsten Verch; Yi Yang; Karl Erik Hellstrom Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-05 Impact factor: 4.254
Authors: Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom Journal: Lancet Date: 2003-11-15 Impact factor: 79.321
Authors: Jenette Creaney; Ivonne van Bruggen; Michelle Hof; Amanda Segal; Arthur W Musk; Nick de Klerk; Nora Horick; Steven J Skates; Bruce W S Robinson Journal: Chest Date: 2007-07-23 Impact factor: 9.410
Authors: Zachary W Kendrick; Matthew A Firpo; Robert C Repko; Courtney L Scaife; Douglas G Adler; Kenneth M Boucher; Sean J Mulvihill Journal: HPB (Oxford) Date: 2013-12-06 Impact factor: 3.647
Authors: Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen Journal: PLoS One Date: 2012-07-06 Impact factor: 3.240